Amanote Research

Amanote Research

    RegisterSign In

FDA Critical Path Initiatives: Opportunities for Generic Drug Development

AAPS Journal - United States
doi 10.1208/s12248-008-9010-2
Full Text
Open PDF
Abstract

Available in full text

Categories
Pharmaceutical Science
Date

February 20, 2008

Authors
Robert A. Lionberger
Publisher

Springer Science and Business Media LLC


Related search

Generic Drug Product Development Bioequivalence Issues

Journal of Pharmacy and Pharmaceutical Sciences
MedicinePharmacologyPharmaceutical Science
2008English

Drug Development Process and Novel Drugs Approved by FDA for 2017 -18

Applied Clinical Research, Clinical Trials and Regulatory Affairs
2018English

New FDA Drug Approval Policies and HIV Vaccine Development.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1990English

Novel Opportunities for CFTR-targeting Drug Development Using Organoids

Rare Diseases
2013English

Drug Development in Critical Times

NeuroRX
2006English

2017 FDA Drug Approvals

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2018English

Regional Opportunities and Policy Initiatives for New Venture Creation

Development and Learning in Organizations
Human Resource ManagementOrganizational BehaviorLibraryInformation Sciences
2010English

Drug Suicide Risks Prompt Call for FDA Action

Nature
Multidisciplinary
2004English

OxyContin, the FDA, and Drug Control

AMA journal of ethics
Health PolicyEthicsHealthIssuesLegal Aspects
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy